- Home
- SCYX vs FLUX Comparison
SCYX vs FLUX Comparison
Compare SCYX & FLUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- FLUX
- Stock Information
- Founded
- SCYX 1999
- FLUX N/A
- Country
- SCYX United States
- FLUX United States
- Employees
- SCYX N/A
- FLUX N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- FLUX Industrial Machinery/Components
- Sector
- SCYX Health Care
- FLUX Miscellaneous
- Exchange
- SCYX Nasdaq
- FLUX Nasdaq
- Market Cap
- SCYX 26.6M
- FLUX 25.4M
- IPO Year
- SCYX 2014
- FLUX N/A
- Fundamental
- Price
- SCYX $0.88
- FLUX $1.67
- Analyst Decision
- SCYX
- FLUX Strong Buy
- Analyst Count
- SCYX 0
- FLUX 2
- Target Price
- SCYX N/A
- FLUX $6.00
- AVG Volume (30 Days)
- SCYX 212.7K
- FLUX 81.3K
- Earning Date
- SCYX 08-19-2025
- FLUX 08-19-2025
- Dividend Yield
- SCYX N/A
- FLUX N/A
- EPS Growth
- SCYX N/A
- FLUX N/A
- EPS
- SCYX N/A
- FLUX N/A
- Revenue
- SCYX $2,630,000.00
- FLUX $63,074,000.00
- Revenue This Year
- SCYX $410.22
- FLUX $11.10
- Revenue Next Year
- SCYX $248.83
- FLUX $12.66
- P/E Ratio
- SCYX N/A
- FLUX N/A
- Revenue Growth
- SCYX N/A
- FLUX N/A
- 52 Week Low
- SCYX $0.66
- FLUX $1.15
- 52 Week High
- SCYX $1.82
- FLUX $3.64
- Technical
- Relative Strength Index (RSI)
- SCYX 68.89
- FLUX 46.86
- Support Level
- SCYX $0.68
- FLUX $1.42
- Resistance Level
- SCYX $0.92
- FLUX $1.69
- Average True Range (ATR)
- SCYX 0.04
- FLUX 0.16
- MACD
- SCYX 0.02
- FLUX -0.03
- Stochastic Oscillator
- SCYX 83.33
- FLUX 34.25
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.